|
1.
|
原著(症例報告除く)
|
[Establishment of an Onco-Ophthalmology Collaboration for Tisotumab Vedotin and Initial Experience with Ocular Adverse Events] 2026/07
|
|
2.
|
原著(症例報告除く)
|
Phase II study of ramucirumab plus erlotinib for treatment-naïve patients with EGFR-mutant non-squamous non-small cell lung cancer and pleural effusion (RELAY-Effusion). 2026/07
|
|
3.
|
その他
|
Should supportive care be started before initiating cancer treatment? 2026/07
|
|
4.
|
原著(症例報告除く)
|
Tisotumab Vedotin導入におけるOnco-Ophthalmology連携体制の構築と眼有害事象の初期経験 2026/07
|
|
5.
|
原著(症例報告除く)
|
AGTR1 signaling contributes to tumor immunity and therapy response in non-small cell lung cancer. 2026/05
|
|
6.
|
原著(症例報告除く)
|
Clinical trajectory of KRAS G12C-mutated advanced non-small cell lung cancer: a single-center cohort study in Japan 2026/04
|
|
7.
|
総説
|
Survival, Toxicity, and Sequencing: Navigating the New First-Line Standard Established by FLAURA2 2026/04
|
|
8.
|
その他
|
【日常診療に必要な呼吸器関連の臨床検査のアップデート】腫瘍随伴症候群 2026/04
|
|
9.
|
総説
|
Why Cemiplimab? Defining a Unique Therapeutic Niche in First-Line Non-Small-Cell Lung Cancer with Ultra-High PD-L1 Expression and Squamous Histology 2026/01
|
|
10.
|
原著(症例報告除く)
|
Exploratory analysis of associations among weight loss, oral function, and dysgeusia in patients with lung cancer undergoing chemotherapy. 2025/12
|
|
11.
|
原著(症例報告除く)
|
Impact of the Lung Immune Prognostic Index in non-small-cell lung cancer patients with PD-L1-low/negative tumors receiving chemoimmunotherapy: a real-world multicenter retrospective study. 2025/12
|
|
12.
|
原著(症例報告除く)
|
Multicenter retrospective study of selpercatinib treatment for advanced or recurrent RET fusion-positive non-small cell lung cancer in Japan. 2025/12
|
|
13.
|
原著(症例報告除く)
|
PD-L1 phenotype classification based on expression in tumor and immune cells as a potential biomarker for optimizing anti-PD-1/CTLA-4 immunotherapies in NSCLC. 2025/12
|
|
14.
|
原著(症例報告除く)
|
Anamorelin in Cancer Cachexia: Gut Microbiota Effects and CONUT Score as a Predictor of Response. 2025/11
|
|
15.
|
原著(症例報告除く)
|
Pharmacokinetics and bioavailability of pembrolizumab with berahyaluronidase alfa for subcutaneous administration in participants with advanced or metastatic solid tumors: The phase 1 study 3475A-C18. 2025/11
|
|
16.
|
原著(症例報告除く)
|
肺がん患者および家族における体重減少とがん悪液質の認識に関する実態調査 2025/10
|
|
17.
|
原著(症例報告除く)
|
Combined effects of slow movement training with tonic force generation and aerobic exercise prior to cancer therapy in patients with lung cancer (START-lung): a pilot feasibility trial. 2025/09
|
|
18.
|
原著(症例報告除く)
|
A treatment-related death predictive score for treatment-naïve advanced non-small cell lung cancer. 2025/06
|
|
19.
|
原著(症例報告除く)
|
Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834 2025/06
|
|
20.
|
原著(症例報告除く)
|
Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-doublet Chemotherapy for Non-small Cell Lung Cancer Harboring EGFR Mutation 2025/06
|
|
21.
|
原著(症例報告除く)
|
Impact of time to treatment initiation on the development of cachexia and clinical outcomes in lung cancer 2025/04
|
|
22.
|
原著(症例報告除く)
|
長期生存時代において脳転移を有する再発非小細胞肺癌の定位放射線治療による晩期障害として放射線脳壊死を来した1例 2025/04
|
|
23.
|
原著(症例報告除く)
|
Efficacy of Molecular-targeted Agents in Vertebral Metastasis Management in Non-small Cell Lung Cancer 2025/03
|
|
24.
|
症例報告
|
Salvage Lung Resection of Aspergilloma Mimicking Tumor Regrowth after Immune Checkpoint Inhibitor Therapy for Stage IV Squamous Cell Lung Cancer: A Case Report 2025/03
|
|
25.
|
原著(症例報告除く)
|
Comparative Study on Associations Between Lung Cancer Prognosis and Diagnostic Criteria Set by the European Palliative Care Research Collaboration and the Asian Working Group for Cachexia 2025/01
|
|
26.
|
原著(症例報告除く)
|
Diversity of TCR repertoire predicts recurrence after CRT followed by durvalumab in patients with NSCLC 2025/01
|
|
27.
|
原著(症例報告除く)
|
Study protocol of an open-label prospective phase II study of Durvalumab plus Carboplatin and Etoposide in advanced large cell neuroendocrine carcinoma of the lung (LOGIK2401: NECTAR study). 2025
|
|
28.
|
原著(症例報告除く)
|
Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real-World Evidence 2024/12
|
|
29.
|
原著(症例報告除く)
|
Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial 2024/11
|
|
30.
|
原著(症例報告除く)
|
Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non-small-Cell Lung Cancer in Patients Aged 75 Years and Older 2024/10
|
|
31.
|
原著(症例報告除く)
|
Feasibility Study of Nivolumab in Combination with Carboplatin Plus Paclitaxel and Concurrent Thoracic Radiation in Patients with Untreated Unresectable Locally Advanced Non-Small Cell Lung Cancer 2024/09
|
|
32.
|
総説
|
がん薬物療法の常識を覆した免疫チェックポイント阻害剤 2024/09
|
|
33.
|
原著(症例報告除く)
|
Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up 2024/08
|
|
34.
|
原著(症例報告除く)
|
Safety of immune checkpoint inhibitors in patients aged over 80 years: a retrospective cohort study 2024/05
|
|
35.
|
症例報告
|
神経症状を契機に診断された傍腫瘍性神経症候群関連抗体陽性の小細胞肺癌の2例 2024/04
|
|
36.
|
原著(症例報告除く)
|
Investigation of a practical assessment index to capture the clinical presentation of cachexia in patients with lung cancer 2024/03
|
|
37.
|
その他
|
治療法の再整理とアップデートのために 専門家による私の治療 小細胞肺癌 2024/03
|
|
38.
|
原著(症例報告除く)
|
Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression ≤49%: a multicenter retrospective study 2024/01
|
|
39.
|
原著(症例報告除く)
|
抗VEGF療法関連高血圧に対するアンジオテンシン受容体ネプリライシン阻害薬の有効性の検討 2024
|
|
40.
|
原著(症例報告除く)
|
高齢者進行非小細胞肺がんに対する免疫チェックポイント阻害剤治療 臨床薬理学検討からわかったこと 2024
|
|
41.
|
原著(症例報告除く)
|
進行・再発非小細胞肺癌における化学療法+PD-1/PD-L1阻害薬療法へ薬剤曝露が及ぼす影響 2024
|
|
42.
|
原著(症例報告除く)
|
Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial 2023/11
|
|
43.
|
その他
|
【肺癌に対する薬物治療の最前線】IV期非小細胞肺癌におけるドライバー遺伝子変異陰性例での治療戦略 2023/11
|
|
44.
|
原著(症例報告除く)
|
First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study 2023/10
|
|
45.
|
原著(症例報告除く)
|
Pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer without tumor PD-L1 expression in Asia 2023/09
|
|
46.
|
原著(症例報告除く)
|
Nivolumab+Ipilimumab併用療法によって生じたradiation recall pneumonitisの1例 2023/08
|
|
47.
|
原著(症例報告除く)
|
Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non-small-cell lung cancer in KEYNOTE-407 2023/08
|
|
48.
|
原著(症例報告除く)
|
A Retrospective Study Investigating the Safety and Efficacy of Nanoliposomal Irinotecan in Elderly Patients with Unresectable Pancreatic Cancer 2023/05
|
|
49.
|
原著(症例報告除く)
|
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study 2023/04
|
|
50.
|
原著(症例報告除く)
|
Survival Impact of Second-Line Immune Checkpoint Inhibitors in Older Patients With Advanced Squamous-Cell NSCLC: Post Hoc Analysis of the CAPITAL Study 2023/04
|
|
51.
|
原著(症例報告除く)
|
Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study 2023/02
|
|
52.
|
その他
|
肺がん治療におけるリハビリテーションとチーム医療 外来通院治療を行う肺がん患者に対するリハビリテーションの現状と課題 2022/11
|
|
53.
|
原著(症例報告除く)
|
Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. 2022/04
|
|
54.
|
原著(症例報告除く)
|
Massive digital gene expression analysis reveals different predictive profiles for immune checkpoint inhibitor therapy between adenocarcinoma and squamous cell carcinoma of advanced lung cancer 2022/02
|
|
55.
|
原著(症例報告除く)
|
Phase I study of weekly nab‑paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer. 2022/02
|
|
56.
|
原著(症例報告除く)
|
Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial. 2021/12
|
|
57.
|
原著(症例報告除く)
|
First-line pembrolizumab versus chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset 2021/12
|
|
58.
|
原著(症例報告除く)
|
Outcomes with pembrolizumab plus platinum-based chemotherapy for patients with non–small-cell lung cancer and stable brain metastases: pooled analysis of KEYNOTE-021, 189, and 407. 2021/11
|
|
59.
|
その他
|
【Withコロナ時代の呼吸器疾患診療】Withコロナ時代の肺がん診療 2021/11
|
|
60.
|
原著(症例報告除く)
|
医学と医療の最前線 進行肺癌に対する薬物治療の最前線 2021/11
|
|
61.
|
原著(症例報告除く)
|
Rationale and design for a multicenter, phase II study of Durvalmab plus concurrent radiation therapy in locally advanced non-small cell lung cancer: the DOLPHIN study (WJOG11619L) 2021/10
|
|
62.
|
原著(症例報告除く)
|
Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study 2021/08
|
|
63.
|
症例報告
|
Hypercalcemia Owing to Overproduction of 1,25-Dihydroxyvitamin D 3 in Fetal Lung Adenocarcinoma: Case Report 2021/07
|
|
64.
|
原著(症例報告除く)
|
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189 2021/07
|
|
65.
|
原著(症例報告除く)
|
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial 2021/05
|
|
66.
|
原著(症例報告除く)
|
Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C 2021/05
|
|
67.
|
原著(症例報告除く)
|
Phase I/II Study of Cisplatin plus Nab-Paclitaxel with Concurrent Thoracic Radiotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer 2021/01
|
|
68.
|
原著(症例報告除く)
|
Phase 1 study of pembrolizumab plus chemotherapy as first-line treatment in Japanese patients with advanced non–small-cell lung cancer. 2021
|
|
69.
|
原著(症例報告除く)
|
First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset 2020/12
|
|
70.
|
原著(症例報告除く)
|
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. 2020/11
|
|
71.
|
原著(症例報告除く)
|
Prognostic impact of mucin spread, tumor cell spread, and invasive size in invasive mucinous adenocarcinoma of the lung. 2020/08
|
|
72.
|
原著(症例報告除く)
|
Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study). 2020/05
|
|
73.
|
原著(症例報告除く)
|
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer 2020/03
|
|
74.
|
原著(症例報告除く)
|
Biomarker testing for personalized, first-line therapy in advanced nonsquamous non-small cell lung cancer patients in the real world setting in Japan: a retrospective, multicenter, observational study (the BRAVE study) 2020/02
|
|
75.
|
原著(症例報告除く)
|
Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. 2020/01
|
|
76.
|
原著(症例報告除く)
|
Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study. 2020/01
|
|
77.
|
原著(症例報告除く)
|
Biomarker testing for personalized, first-line therapy in advanced nonsquamous non-small cell lung cancer patients in the real world setting in Japan: a retrospective, multicenter, observational study (the BRAVE study). 2020
|
|
78.
|
原著(症例報告除く)
|
Three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC-update from PACIFIC. 2020
|
|
79.
|
原著(症例報告除く)
|
Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. 2020
|
|
80.
|
その他
|
KEYNOTE-189: OS Update and Progression After the Next Line of Therapy (PFS2) with Pembrolizumab plus Chemotherapy for Metastatic Nonsquamous NSCLC 2019/11
|
|
81.
|
その他
|
Pembrolizumab Plus Chemotherapy for Advanced NSCLC without Tumor PD-L1 Expression: Pooled Analysis of KN021G, KN189 and KN407 2019/11
|
|
82.
|
その他
|
Pembrolizumab plus Pemetrexed-Platinum for Patients with Metastatic Nonsquamous NSCLC and Liver or Brain Metastases: Results from KEYNOTE-189 2019/11
|
|
83.
|
原著(症例報告除く)
|
Brief report: Three-year overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC - Update from PACIFIC. 2019/10
|
|
84.
|
その他
|
Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) in NSCLC with brain metastases: Pooled analysis of KEYNOTE-021, 189, and 407 2019/10
|
|
85.
|
その他
|
Primary results from Japanese phase I study of pembrolizumab plus chemotherapy as front-line therapy for advanced NSCLC 2019/10
|
|
86.
|
その他
|
Randomized Phase II Study of CDDP+S-1 vs CDDP+PEM Combined with Thoracic RT for Locally Advanced Non-Sq NSCLC: SPECTRA Study 2019/10
|
|
87.
|
その他
|
Randomized phase II study of CDDP+S-1 vs CDDP+PEM combined with thoracic RT for locally advanced non-squamous NSCLC 2019/10
|
|
88.
|
原著(症例報告除く)
|
Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA. 2019/08
|
|
89.
|
その他
|
Outcomes among patients (pts) with metastatic nonsquamous NSCLC with liver metastases or brain metastases treated with pembrolizumab (pembro) plus pemetrexed-platinum: Results from the KEYNOTE-189 study 2019/07
|
|
90.
|
原著(症例報告除く)
|
A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for lung cancer. 2019/05
|
|
91.
|
その他
|
First subsequent treatment after discontinuation of durvalumab in unresectable, stage III NSCLC patients from PACIFIC. 2019/05
|
|
92.
|
その他
|
KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC. 2019/05
|
|
93.
|
その他
|
Three-year overall survival update from the PACIFIC trial. 2019/05
|
|
94.
|
その他
|
Osimertinib as first-line (1L) treatment for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC): Final efficacy and safety results from two phase I expansion cohorts 2019/04
|
|
95.
|
その他
|
Safety and tolerability of pembrolizumab or placebo plus pemetrexed and platinum as first-line therapy in Japanese patients (PTS) with metastatic non-squamous non-small cell lung cancer (NSCLC) enrolled in the phase III KEYNOTE-189 study 2019/04
|
|
96.
|
原著(症例報告除く)
|
Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site. 2019/03
|
|
97.
|
その他
|
Evaluation of the re-introducing FOLFOX or XELOX +/- bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study). 2019/02
|
|
98.
|
症例報告
|
Pembrolizumab-induced autoimmune encephalitis in a patient with advanced non-small cell lung cancer: A case report. 2019/02
|
|
99.
|
原著(症例報告除く)
|
Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset. 2019/01
|
|
100.
|
原著(症例報告除く)
|
Osimertinib versus standard-of-care EGFR-TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA Asian subset. 2019/01
|
|
101.
|
原著(症例報告除く)
|
Exploration of resistance mechanisms for EGFR-TKIs based on plasma analysis by digital PCR and next-generation sequencing. 2018/12
|
|
102.
|
原著(症例報告除く)
|
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. 2018/12
|
|
103.
|
原著(症例報告除く)
|
Comparative study of programmed cell death ligand-1 immunohistochemistry assays using 22C3 and 28-8 antibodies for non-small cell lung cancer: Analysis of 420 surgical specimens from Japanese patients. 2018/11
|
|
104.
|
その他
|
術後肺転移を生じた胸腺原発adenocarcinoma、NOSの1例(会議録) 2018/10
|
|
105.
|
原著(症例報告除く)
|
A Randomized Phase III Study Comparing Carboplatin With Nab-Paclitaxel Versus Docetaxel for Elderly Patients With Squamous-Cell Lung Cancer: Study Protocol. 2018/09
|
|
106.
|
原著(症例報告除く)
|
An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors 2018/09
|
|
107.
|
原著(症例報告除く)
|
Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer. 2018/08
|
|
108.
|
原著(症例報告除く)
|
Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab. 2018/08
|
|
109.
|
原著(症例報告除く)
|
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. 2018/05
|
|
110.
|
原著(症例報告除く)
|
Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset. 2018/04
|
|
111.
|
原著(症例報告除く)
|
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. 2018/03
|
|
112.
|
原著(症例報告除く)
|
Platelet-related indices in patients with lung cancer with nivolumab. 2018/03
|
|
113.
|
原著(症例報告除く)
|
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. 2018/01
|
|
114.
|
症例報告
|
Combined small cell lung carcinoma and giant cell carcinoma: a case report. 2017/12
|
|
115.
|
原著(症例報告除く)
|
Retrospective analysis of single-agent nab-paclitaxel in patients with platinum-resistant non-small cell lung cancer. 2017/11
|
|
116.
|
原著(症例報告除く)
|
Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer. 2017/10
|
|
117.
|
その他
|
Atezolizumab as 1L therapy for advanced NSCLC in PD-L1-selected patients: updated ORR, PFS and OS data from the BIRCH study 2017/09
|
|
118.
|
その他
|
Safety data from randomized phase II study of cisplatin (CDDP)+S-1 versus CDDP plus pemetrexed (PEM) combined with thoracic radiotherapy (TRT) for locally advanced non-squamous (non-sq) non-small cell lung cancer (NSCLC): SPECTRA study 2017/09
|
|
119.
|
原著(症例報告除く)
|
Interstitial Lung Disease Following Single-Agent Nanoparticle Albumin-Bound Paclitaxel Treatment in Patients with Advanced Non-Small Cell Lung Cancer 2017/08
|
|
120.
|
原著(症例報告除く)
|
New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer. 2017/08
|
|
121.
|
原著(症例報告除く)
|
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH) 2017/08
|
|
122.
|
その他
|
Clinical significance of thrombosis-related biomarkers for patients with non-small-cell lung cancer 2017/05
|
|
123.
|
原著(症例報告除く)
|
Phase I/II study of erlotinib, carboplatin, pemetrexed, and bevacizumab in chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer harboring epidermal growth factor receptor mutation 2017/05
|
|
124.
|
原著(症例報告除く)
|
Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations 2017/01
|
|
125.
|
原著(症例報告除く)
|
Detection of epidermal growth factor receptor gene T790M mutation in cytology samples using the cobas® EGFR mutation test. 2017
|
|
126.
|
原著(症例報告除く)
|
ORAL01.04: Phase II Trial of Atezolizumab for Patients with PD-L1-Selected Advanced NSCLC (BIRCH): Updated Efficacy and Exploratory Biomarker Results: Topic: Medical Oncology. 2016/11
|
|
127.
|
原著(症例報告除く)
|
Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study 2016/11
|
|
128.
|
その他
|
Carboplatin (Cb) plus nab-paclitaxel (PTX) versus docetaxel (D) for elderly squamous (Sq) non-small cell lung cancer (NSCLC) (CAPITAL study) 2016/10
|
|
129.
|
原著(症例報告除く)
|
Retrospective analysis of bevacizumab-induced hypertension and clinical outcome in patients with colorectal cancer and lung cancer 2016/07
|
|
130.
|
原著(症例報告除く)
|
LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts. 2016/04
|
|
131.
|
総説
|
巻頭言 2016年，肺癌治療新時代の幕開け 2016/02
|
|
132.
|
その他
|
【免疫療法の今後の発展と課題】 免疫療法における殺細胞性抗がん剤/放射線治療との併用療法の可能性 2016/01
|
|
133.
|
その他
|
薬剤性間質性肺炎のマネジメント 2015/12
|
|
134.
|
原著(症例報告除く)
|
A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors 2015/10
|
|
135.
|
その他
|
第3世代EGFRチロシンキナーゼ阻害剤について 2015/05
|
|
136.
|
原著(症例報告除く)
|
Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors 2015/04
|
|
137.
|
原著(症例報告除く)
|
A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer 2015/03
|
|
138.
|
原著(症例報告除く)
|
Efficacy and Safety of Continuing Bevacizumab beyond Disease Progression plus Docetaxel in Patients with Non-Small Cell Lung Cancer: A Retrospective Analysis 2015/03
|
|
139.
|
原著(症例報告除く)
|
The role of smoking status on the progression-free survival of non-small-cell lung cancer patients harboring activating Epidermal Growth Factor Receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum double chemotherapy: a meta-analysis of prospective randomized trials 2015/03
|
|
140.
|
原著(症例報告除く)
|
Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a Phase 1 study in Japanese patients with previously treated non-small-cell lung cancer 2015/02
|
|
141.
|
症例報告
|
EGFR遺伝子変異とEML4-ALK融合遺伝子のいずれもが陽性であった肺腺癌の一症例 2014/12
|
|
142.
|
症例報告
|
EML4-ALK転座陽性の扁平上皮肺癌の一例 2014/12
|
|
143.
|
原著(症例報告除く)
|
Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer 2014/12
|
|
144.
|
総説
|
ジオトリフをどう使いこなすか? 2014/12
|
|
145.
|
症例報告
|
肺原発の悪性黒色腫の一例 2014/12
|
|
146.
|
原著(症例報告除く)
|
Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: Phase I study in Japanese patients with advanced solid malignancies and advanced breast cancer 2014/10
|
|
147.
|
総説
|
化学療法に伴う腎毒性 2014/05
|
|
148.
|
総説
|
進行・再発非小細胞肺癌に対する個別化治療の進歩 2014/05
|
|
149.
|
原著(症例報告除く)
|
An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors. 2014/03
|
|
150.
|
原著(症例報告除く)
|
Human Papilloma virus in non-small cell lung cancer in never smokers: A systematic review of the literature. 2014/01
|
|
151.
|
原著(症例報告除く)
|
Role of Is consolidation chemotherapy after concurrent chemo-radiotherapy in locally advanced non-small-cell lung cancer. 2014/01
|
|
152.
|
その他
|
がんについてもっと勉強したい 分子標的治療でがんは治るようになる?ならない? 2013/10
|
|
153.
|
原著(症例報告除く)
|
Is Consolidation Chemotherapy after Concurrent Chemo-Radiotherapy Beneficial for Patients with Locally Advanced Non-Small-Cell Lung Cancer?: A Pooled -Analysis of the Literature. 2013/08
|
|
154.
|
その他
|
Clinical Response to Crizotinib Retreatment After Acquisition of Drug Resistance 2013/07
|
|
155.
|
原著(症例報告除く)
|
Practical Use of gemcitabine and cisplatin combination therapy as first-line treatment for Japanese patients with advanced biliary tract cancer 2013/07
|
|
156.
|
原著(症例報告除く)
|
A phase I study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer 2013/06
|
|
157.
|
原著(症例報告除く)
|
Phase 2 Study of S-1 and Carboplatin Plus Bevacizumab Followed by Maintenance S-1 and Bevacizumab for Chemotherapy-Naive Patients With Advanced Nonsquamous Non–Small Cell Lung Cancer 2013/06
|
|
158.
|
原著(症例報告除く)
|
A Microarray-Based Gene Expression Analysis to Identify Diagnostic Biomarkers for Unknown Primary Cancer. 2013/05
|
|
159.
|
原著(症例報告除く)
|
First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours. 2013/02
|
|
160.
|
原著(症例報告除く)
|
Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor. 2013/01
|
|
161.
|
原著(症例報告除く)
|
A phase I/II study of carboplatin plus gemcitabine for elderly patients with advanced non-small cell lung cancer: West Japan Thoracic Oncology Group Trial (WJTOG) 2905. 2012
|
|
162.
|
原著(症例報告除く)
|
A phase III study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903). 2012
|
|
163.
|
症例報告
|
Capecitabine plus cisplatin treatment for advanced gastric cancer in a patient with hepatic impairment secondary to metastases. 2012
|
|
164.
|
総説
|
Efficacy and safety of denosumab for the treatment of bone metastases in patients with advanced cancer. 2012
|
|
165.
|
原著(症例報告除く)
|
Randomized phase II study of carboplatin-paclitaxel or gemcitabine-vinorelbine in patients with advanced non small cell lung cancer and a performance status of 2: West Japan Thoracic Oncology Group 0004. 2012
|
|
166.
|
原著(症例報告除く)
|
当科における肺門および縦隔リンパ節腫大の診断におけるEBUS-TBNAの有用性の検討 2012
|
|
5件表示
|
|
全件表示(166件)
|
